Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer.

Pollard, Matthew E; Moskowitz, Alan J; Diefenbach, Michael A; Hall, Simon J

Pollard, Matthew E; Moskowitz, Alan J; Diefenbach, Michael A; Hall, Simon J.

Afiliación

Pollard ME; Department of Urology, UCLA School of Medicine, Los Angeles, CA, USA.
Moskowitz AJ; Department of Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY, USA.
Diefenbach MA; Smith Institute for Urology, Hofstra Northwell School of Medicine, Lake Success, NY, USA.
Hall SJ; Smith Institute for Urology, Hofstra Northwell School of Medicine, Lake Success, NY, USA.

Asian J Urol ; 4(1): 37-43, 2017 Jan.

Article en En | MEDLINE | ID: mdl-29264205

Palabras clave

Costs and cost analysis; Economics; Health expenditures; Metastatic prostate cancer; Pharmaceutical

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Guideline / Health_economic_evaluation Idioma: En Revista: Asian J Urol Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google